This document is page 34 of a Cowen 'Collaborative Insights' market research report dated February 25, 2019. It analyzes the packaging and pricing of CBD gummy products from four different companies: CV Sciences, Green Roads, Highline Wellness, and cbdMD. The document bears a 'HOUSE_OVERSIGHT_024850' Bates stamp, indicating it was part of a document production to the House Oversight Committee, though the content appears to be standard equity research unrelated to criminal activity.
| Name | Role | Context |
|---|---|---|
| Michael Cella | Recipient/Employee |
Named in the watermark as the intended recipient of the report (michael.cella@cowen.com).
|
| Name | Type | Context |
|---|---|---|
| Cowen |
Financial services firm that produced the Collaborative Insights report.
|
|
| CV Sciences |
Company whose product is analyzed in Figure 44.
|
|
| Green Roads |
Company whose product is analyzed in Figure 45.
|
|
| Highline Wellness |
Company whose product is analyzed in Figure 46.
|
|
| cbdMD |
Company whose product is analyzed in Figure 47.
|
|
| House Oversight Committee |
Implied by the Bates stamp 'HOUSE_OVERSIGHT_024850'.
|
| Location | Context |
|---|---|
|
Label on cbdMD bottle says 'MADE IN THE U.S.A.'
|
"CV Sciences Gummies Are Priced At A Premium"Source
"Green Roads' 300 MG Gummies Retail For $55"Source
"Highline Is Priced Competitively"Source
"This report is intended for michael.cella@cowen.com. Unauthorized redistribution of this report is prohibited."Source
Complete text extracted from the document (886 characters)
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document